Current treatments for PML rely on some small proportion of cells to express WT p53 such that the arsenic trioxide plus all-trans-retinoic acid can modify the WT p53 protein from a repressor to an initiator of senescence, which is necessary to either kill the PML cells or kickstart the differentiation of PML cancer cells to neutrophils (Levine, 2022). This evidence concerns the gene TP53 and cancer.